| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c63fcd992f4eb4cc1c1938bfb0c01ae0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P23-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 |
| filingDate |
2014-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09ba0faadac4eb0aad2b6cc44ce67e07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd47789d4a8f5737981de644b82bbb70 |
| publicationDate |
2019-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2727292-T3 |
| titleOfInvention |
Combined formulations of neosaxitonin for prolonged local anesthesia |
| abstract |
Dosing unit for use in the treatment or prevention of pain in an awake, sedated or anesthetized human being comprising an effective amount of - between 5 and 40 μg of neosaxitoxin (NeoSTX); - a local anesthetic selected from the group consisting of bupivacaine, levobupivacaine and ropivacaine in a concentration range between 0.1% (1 mg / ml) and 0.5% (5 mg / ml); and - epinephrine in a concentration range between 2 μg / ml (1: 500,000) and 10 μg / ml (1: 100,000); to produce a minimum effective concentration at the site of administration between 0.1-1 μg of NeoSTX / ml. |
| priorityDate |
2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |